VIRsiRNAdb: a curated database of experimentally validated viral siRNA/shRNA

RNAi technology has been emerging as a potential modality to inhibit viruses during past decade. In literature a few siRNA databases have been reported that focus on targeting human and mammalian genes but experimentally validated viral siRNA databases are lacking. We have developed VIRsiRNAdb, a manually curated database having comprehensive details of 1358 siRNA/shRNA targeting viral genome regions. Further, wherever available, information regarding alternative efficacies of above 300 siRNAs derived from different assays has also been incorporated. Important fields included in the database are siRNA sequence, virus subtype, target genome region, cell type, target object, experimental assay, efficacy, off-target and siRNA matching with reference viral sequences. Database also provides the users with facilities of advance search, browsing, data submission, linking to external databases and useful siRNA analysis tools especially siTarAlign which align the siRNA with reference viral genomes or user defined sequences. VIRsiRNAdb contains extensive details of siRNA/shRNA targeting 42 important human viruses including influenza virus, hepatitis B virus, HPV and SARS Corona virus. VIRsiRNAdb would prove useful for researchers in picking up the best viral siRNA for antiviral therapeutics development and also for developing better viral siRNA design tools. The database is freely available at http://crdd.osdd.net/servers/virsirnadb.

[1]  Anitha Rao,et al.  RNA-Based Gene Therapy for HIV with Lentiviral Vector–Modified CD34+ Cells in Patients Undergoing Transplantation for AIDS-Related Lymphoma , 2010, Science Translational Medicine.

[2]  Kazuhiko Hayashi,et al.  siRNA‐resistance in treated HCV replicon cells is correlated with the development of specific HCV mutations , 2006, Journal of viral hepatitis.

[3]  Szymon M. Kielbasa,et al.  HuSiDa—the human siRNA database: an open-access database for published functional siRNA sequences and technical details of efficient transfer into recipient cells , 2004, Nucleic Acids Res..

[4]  Arndt Borkhardt,et al.  RNA interference: new mechanisms for targeted treatment? , 2003, Reviews in clinical and experimental hematology.

[5]  S. Abdolhamid Angaji,et al.  Application of RNA interference in treating human diseases , 2010, Journal of Genetics.

[6]  Ram I Mahato,et al.  siRNA pool targeting different sites of human hepatitis B surface antigen efficiently inhibits HBV infection. , 2008, Journal of drug targeting.

[7]  Xin Zheng,et al.  BIOINFORMATICSAPPLICATIONS NOTE doi:10.1093/bioinformatics/btl026 Databases and ontologies , 2005 .

[8]  A. Fire,et al.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.

[9]  Manoj Kumar,et al.  HIVsirDB: A Database of HIV Inhibiting siRNAs , 2011, PloS one.

[10]  E. Holmes,et al.  Rates of evolutionary change in viruses: patterns and determinants , 2008, Nature Reviews Genetics.

[11]  David V. Schaffer,et al.  Antiviral RNAi: Translating Science Towards Therapeutic Success , 2011, Pharmaceutical Research.

[12]  P. Linsley,et al.  Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application , 2010, Nature Reviews Drug Discovery.

[13]  Yuki Naito,et al.  Optimal design and validation of antiviral siRNA for targeting HIV-1 , 2007, Retrovirology.

[14]  Rob Lambkin-Williams,et al.  A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus , 2010, Proceedings of the National Academy of Sciences.

[15]  Ben Berkhout,et al.  Nucleic Acids-Based Therapeutics in the Battle Against Pathogenic Viruses , 2009, Handbook of experimental pharmacology.

[16]  Ben Berkhout,et al.  Human Immunodeficiency Virus Type 1 Escapes from RNA Interference-Mediated Inhibition , 2004, Journal of Virology.

[17]  G Narahari Sastry,et al.  DSTHO: database of siRNAs targeted at human oncogenes: a statistical analysis. , 2006, International journal of biological macromolecules.

[18]  Michael Zuker,et al.  Mfold web server for nucleic acid folding and hybridization prediction , 2003, Nucleic Acids Res..

[19]  D. Schaffer,et al.  Antiviral RNAi therapy: emerging approaches for hitting a moving target , 2005, Gene Therapy.

[20]  Erik L. L. Sonnhammer,et al.  siRNA specificity searching incorporating mismatch tolerance data . – Supplementary Data , 2008 .

[21]  W. Filipowicz,et al.  RNAi: The Nuts and Bolts of the RISC Machine , 2005, Cell.

[22]  Erik L. L. Sonnhammer,et al.  siRNAdb: a database of siRNA sequences , 2004, Nucleic Acids Res..

[23]  Anastasia Khvorova,et al.  Addendum: 3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets , 2006 .

[24]  Anastasia Khvorova,et al.  3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets , 2006, Nature Methods.

[25]  Ben Berkhout,et al.  Lentiviral Vector Design for Multiple shRNA Expression and Durable HIV-1 Inhibition , 2008, Molecular Therapy.

[26]  M. Kimmel,et al.  Conflict of interest statement. None declared. , 2010 .

[27]  John Maraganore,et al.  A status report on RNAi therapeutics , 2010, Silence.

[28]  P. Arbuthnot,et al.  Harnessing RNA interference for the treatment of viral infections. , 2010, Drug news & perspectives.

[29]  D. Haussecker,et al.  The business of RNAi therapeutics. , 2008, Human gene therapy.

[30]  I. Longden,et al.  EMBOSS: the European Molecular Biology Open Software Suite. , 2000, Trends in genetics : TIG.

[31]  Eugene W. Myers,et al.  Optimal alignments in linear space , 1988, Comput. Appl. Biosci..

[32]  R. Tripp,et al.  Therapeutic applications of RNAi for silencing virus replication. , 2009, Methods in molecular biology.

[33]  B. Berkhout,et al.  RNA interference against viruses: strike and counterstrike , 2007, Nature Biotechnology.

[34]  Mario Stevenson,et al.  Therapeutic potential of RNA interference. , 2004, The New England journal of medicine.

[35]  Michael T. McManus,et al.  RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Heuiran Lee,et al.  Antiviral potency of a siRNA targeting a conserved region of coxsackievirus A24. , 2008, Biochemical and biophysical research communications.

[37]  Catherine H. Wu,et al.  Inhibition of HBV replication by siRNA in a stable HBV‐producing cell line , 2003, Hepatology.

[38]  Erik L. L. Sonnhammer,et al.  siRNA specificity searching incorporating mismatch tolerance data , 2008, Bioinform..

[39]  Christopher D. Richardson,et al.  Hepatitis C Virus Replicons Escape RNA Interference Induced by a Short Interfering RNA Directed against the NS5b Coding Region , 2005, Journal of Virology.

[40]  K. Ui-Tei,et al.  Thermodynamic stability and Watson–Crick base pairing in the seed duplex are major determinants of the efficiency of the siRNA-based off-target effect , 2008, Nucleic acids research.

[41]  B. Li,et al.  Expression profiling reveals off-target gene regulation by RNAi , 2003, Nature Biotechnology.

[42]  Beverly L. Davidson,et al.  Current prospects for RNA interference-based therapies , 2011, Nature Reviews Genetics.

[43]  Anastasia Khvorova,et al.  Experimental validation of the importance of seed complement frequency to siRNA specificity. , 2008, RNA.

[44]  E. Myers,et al.  Basic local alignment search tool. , 1990, Journal of molecular biology.

[45]  S. Kauppinen,et al.  Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection , 2010, Science.

[46]  Yuki Naito,et al.  siVirus: web-based antiviral siRNA design software for highly divergent viral sequences , 2006, Nucleic Acids Res..

[47]  Jie Xiong,et al.  Inhibition of genes expression of SARS coronavirus by synthetic small interfering RNAs , 2005, Cell Research.

[48]  M. López‐Fraga,et al.  RNA Interference Technologies and Therapeutics , 2012, BioDrugs.